Ask AI

Independent Conference Coverage of CROI 2026: The Latest Updates in HIV *

This program summarizes key data and highlights from the 2026 Conference on Retroviruses and Opportunistic Infections (CROI).

Share

Program Content

Events

14 Capsule Summaries

Activities

MK 8591A 052 Wk 96 DOR and ISL
MK-8591A-052 Week 96: Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2026

MK 8591A 051 Wk 96
MK-8591A-051 Wk 96: Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2026

OPERA PrEP
OPERA Cohort: PrEP Coverage and HIV Incidence With LA CAB vs Daily Oral FTC/TDF or FTC/TAF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ARTISTRY-1
ARTISTRY-1: Phase III Trial of Single-Tablet BIC/LEN Switch vs Complex ART Continuation in People With HIV and Virologic Suppression
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ARTISTRY-2
ARTISTRY-2: Phase III Trial of Single-Tablet BIC/LEN Switch vs BIC/FTC/TAF Continuation in People With HIV and Virologic Suppression
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

LEN Case Series
Case Series Evaluating Long-acting Lenacapavir in People With HIV and High Baseline Resistance
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

ANRS Prevenir
ANRS Prévenir: Final Results of Prospective Observational Cohort Study of Daily or On-Demand Oral FTC/TDF HIV PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

MK-8527 PrEP
MK-8527 PrEP: Phase I-II PK Analysis to Inform Dosing for EXPrESSIVE Phase III Trial Program
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

LA CAB + RPV in Adolescents
IMPAACT 2017 Cohort 2: Wk 96 and End-of-Study Data After Switch to LA CAB + RPV in Adolescents Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Lenacapavir PrEP in Adolescent and Young Women
PURPOSE 1: Long-term Follow-up of Twice-Yearly Lenacapavir PrEP in Adolescent and Young Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Purpose 2 Longer Term Analysis
PURPOSE 2 Longer-Term Analysis: Phase III Trial of HIV PreP With Twice-Yearly LEN vs Daily FTC/TDF in Cisgender Men and Gender Diverse People
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

LEN Resistance Mutations in PURPOSE
PURPOSE 1 and PURPOSE 2: Randomized Blinded Phase Resistance Analysis With LEN PrEP
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

VOLITION
VOLITION Primary Analysis: Phase III Trial of Early LA CAB + RPV Switch After Achieving Virologic Suppression With DTG/3TC in Treatment-Naive Adults With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

EMBRACE
EMBRACE: 12 Mo Results With Lotivibart + LA CAB for People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

*Decera Clinical Education is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.